Kyntra Bio
KYNB
68 hedge funds and large institutions have $19.2M invested in Kyntra Bio in 2024 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 21 reducing their positions, and 14 closing their positions.
300% more call options, than puts
Call options by funds: $336K | Put options by funds: $84K
2% more capital invested
Capital invested by funds: $18.9M → $19.2M (+$342K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.39% less ownership
Funds ownership: 1.83% → 1.44% (-0.39%)
3% less funds holding
Funds holding: 70 → 68 (-2)
14% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 14
33% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$225K |
| 2 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$164K |
| 3 |
Squarepoint
New York
|
+$144K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$63.9K |
| 5 |
Two Sigma Advisers
New York
|
+$50.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
-$1.97M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$842K |
| 3 |
JP Morgan Chase
New York
|
-$622K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$438K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$155K |
KYNB Hedge Fund Activity: Q4 2024 in Review
68 of the 7,605 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q4 2024, worth a combined $19.2M — up 1.8% from $18.9M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of KYNB and 12 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 14 added.
The largest buyer was Renaissance Technologies, adding an estimated $225K. The largest seller was Primecap Management, cutting an estimated $1.97M.
- 68 institutional investors held Kyntra Bio (KYNB) as of Q4 2024, down from 70 in Q3 2024.
- Funds reported $19.2M of Kyntra Bio stock for Q4 2024, up 1.8% quarter-over-quarter.
- 12 funds opened new Kyntra Bio positions in Q4 2024 and 14 closed out, a net change of -2 holders.
- The largest Kyntra Bio buyer in Q4 2024 was Renaissance Technologies, an estimated $225K added.
- The largest Kyntra Bio seller in Q4 2024 was Primecap Management, an estimated $1.97M sold.
Based on aggregated 13F filings for Q4 2024.